Literature DB >> 15019161

Inhibition of transforming growth factor-beta and matrix metalloproteinases by estrogen and prolactin in breast cancer cells.

Neena Philips1, Karyn McFadden.   

Abstract

Hormones, estrogen and prolactin, transforming growth factor-beta (TGF-beta), and matrixmetalloproteinases (MMPs) may modulate breast cancer progression. The goal of this research was to examine the regulation of expression of TGF-beta and MMPs (MMP-1, 2, 9) by estrogen and prolactin, independently and in combination, at physiological doses, and at doses stimulating cancer cell (T47D) proliferation in vitro. Prolactin, and estrogen synergistically, and similarly, inhibited the expression of TGF-beta and MMPs at physiological concentrations without altering cell proliferation, indicating a beneficial role of the hormones. The growth stimulating concentration of prolactin, but not estrogen, also inhibited the TGF-beta and MMP expression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15019161     DOI: 10.1016/j.canlet.2003.10.019

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  7 in total

1.  Human scalp hair follicles are both a target and a source of prolactin, which serves as an autocrine and/or paracrine promoter of apoptosis-driven hair follicle regression.

Authors:  Kerstin Foitzik; Karoline Krause; Franziska Conrad; Motonobu Nakamura; Wolfang Funk; Ralf Paus
Journal:  Am J Pathol       Date:  2006-03       Impact factor: 4.307

2.  Plasma matrix metalloproteinase 2 levels and breast cancer risk.

Authors:  Sarah A Aroner; Bernard A Rosner; Rulla M Tamimi; Shelley S Tworoger; Nadja Baur; Thomas O Joos; Susan E Hankinson
Journal:  Cancer Epidemiol       Date:  2015-03-19       Impact factor: 2.984

3.  A mechanistic study of the effect of doxorubicin/adriamycin on the estrogen response in a breast cancer model.

Authors:  Jessica E Pritchard; Patrick M Dillon; Mark R Conaway; Corinne M Silva; Sarah J Parsons
Journal:  Oncology       Date:  2012-09-05       Impact factor: 2.935

4.  Determination of TGFbeta1 protein level in human primary breast cancers and its relationship with survival.

Authors:  S Desruisseau; J Palmari; C Giusti; S Romain; P-M Martin; Y Berthois
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640

5.  Threonine 32 (Thr32) of FoxO3 is critical for TGF-β-induced apoptosis via Bim in hepatocarcinoma cells.

Authors:  Xiangxuan Zhao; Yong Liu; Lei Du; Leya He; Biyun Ni; Junbo Hu; Dahai Zhu; Quan Chen
Journal:  Protein Cell       Date:  2014-12-11       Impact factor: 14.870

6.  Decrease of lactogenic hormones induce epithelial-mesenchymal transition via TGFβ1 and arachidonic acid during mammary gland involution.

Authors:  Haolin Zhang; Yuning Liu; Ji Weng; Kento Usuda; Kazuki Fujii; Gen Watanabe; Kentaro Nagaoka
Journal:  J Reprod Dev       Date:  2017-04-04       Impact factor: 2.214

7.  Beneficial Regulation of Cellular Oxidative Stress Effects, and Expression of Inflammatory, Angiogenic, and the Extracellular Matrix Remodeling Proteins by 1α,25-Dihydroxyvitamin D3 in a Melanoma Cell Line.

Authors:  Neena Philips; Philips Samuel; Thomas Keller; Asma Alharbi; Samar Alshalan; Sara-Ali Shamlan
Journal:  Molecules       Date:  2020-03-05       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.